Neeraj Agarwal, Postdoctoral fellow at City of Hope, shared a post on X:
“Congrats Andrew Armstrong for the 5-yr follow-up OS results from ph3 Arches trial in mHSPC prostate cancer with enzalutamide. 66% probability of survival at 5 yrs & 30% reduction of risk of death with enzalutamide.”
Read OncoDaily’s Special Articles about ASCO 2025:
Highlights from ASCO 2025 Day 1
Highlights from ASCO 2025 Day 2
